** Shares in Carmat ALCAR.PA jump more than 9% after the
French artificial heart maker said it had implanted seven of its
Aeson devices as part of a clinical study in Paris
** The company, which this month received a 7 million euro
($7.4 million) lifeline to avert an imminent cash crunch, said
the pace of implants means it will be able to complete the study
in 2025, in line with its targets
** The stock tracks its best day since early July
** The shares in Carmat, which had dropped almost 70% this
year, were up 9.1% at 3.4 euros as of 0812 GMT
(Reporting by Michal Aleksandrowicz)
((michal.aleksandrowicz@tr.com))